Paradoxically, mesenchymal tumors, such as triple-negative breast cancers, appear more responsive to ICB immunotherapy than do epithelial cancers, such as HER2+ breast cancer (Nanda et al. 2020). This evidence concerns the gene ERBB2 and breast cancer.